Andere Sprachen Granules India Limited

Aktien

A14QQF

INE101D01020

GRANULES

Markt geschlossen - Bombay S.E. Andere Börsenplätze 12:00:50 06.05.2024			% 5 Tage	% 1. Jan.
422,4 ^INR	-0,24 %		+0,51 %	+4,18 %

30.04.	Granules Pharmaceuticals Arm erhält US FDA-Zulassung für generisches Medikament gegen Gichtschübe	MT
03.04.	Granules India Unit erhält VAI-Status für Anlage in Virginia	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Granules India : ANDA Approval for Colchicine Capsules 0.6 mg	30.04.
Granules Pharmaceuticals Arm Gets US FDA's Approval for Generic Drug for Gout Flares	30.04.
Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit	15.04.
Granules India Unit Gets VAI Status for Virginia Facility	03.04.
Granules India Limited Announces Appointment of Directors	02.04.
Granules India Limited Announces Cessation of Arun Rao Akinepally as Independent Director	29.03.
Granules India Limited Announces Appointment of Sethu Madhavan Sankaran as Senior Vice President - Api Manufacturing & Operations	29.03.
Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer	11.03.
Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing	05.03.
Paracetamol maker Granules India posts marginal rise in Q3 profit	23.01.
Granules India's Posts Gains in Fiscal Q3 Consolidated Net Profit	23.01.
Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	23.01.
Granules Pharmaceuticals Unit's Virginia Facility Gets Five Observations from US FDA	18.12.
Granules India Gets US FDA Nod for Pantoprazole Sodium Delayed-Release Tablets	13.12.
Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets	13.12.
Granules India Arm Gets US FDA Nod for Sildenafil for Oral Suspension	04.12.
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand	09.11.
Granules India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09.11.
Granules India : Received ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules	19.10.23
Granules India Gets US FDA's Approval for Generic Drug for GERD Symptoms	19.10.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Granules India Limited

Aktien

A14QQF

INE101D01020

GRANULES

Andere Sprachen

Filter